Business Wire

Business Leaders Do Not Trust Each Others' Climate Claims - Inmarsat Research

Share

Most business leaders (76%) in major industries doubt their peers’ Environmental, Social and Governance (ESG) reporting, according to a new study by Inmarsat, the world leader in global, mobile satellite communications.

The findings come from a new global, independent research report Accelerating sustainable action through IoT commissioned by the company. It explores the views of over 1,000 senior technology and ESG decision-makers across agriculture, mining, transport, utilities and oil & gas firms. The survey asked professionals about their perceptions on ESG and whether they believed data provided by ‘Internet of Things’ (IoT) solutions could help improve reporting transparency.

Respondents also report concerns about their peers’ ESG priorities, with 80% saying their competitors are more focused on perception rather than achieving tangible sustainability outcomes.

However, despite scepticism about the motivations of their peers, most business leaders have faith in their own initiatives: with 81% convinced their company is more sustainable than their competitors.

LACK OF DATA DRIVING LACK OF TRUST

The results suggest that a lack of verifiable hard data – and the willingness to share it – is undermining trust and slowing progress on business sustainability.

Positively, however, many believe data collected via IoT solutions is critical to building trust (81%) and improving ESG outcomes overall (82%).

Four in five respondents plan to increase their use of IoT solutions over the next 12 months to measure and understand the impact of their sustainability initiatives more accurately. A similar proportion reported they are already seeing return on investment from IoT tools used to improve sustainability (78%).

While the majority (83%) agree they could be doing more to effectively leverage IoT solutions to produce ESG data, engrained resistance to data sharing creates an additional barrier to progress.

Only 47% said they would be comfortable sharing all their ESG data with third parties to improve industry reporting and benchmarking over the next 1-3 years, reinforcing that improving trust will be key to achieving better outcomes.

SATELLITE CONNECTIVITY KEY FOR IOT

With big data at the heart of IoT effectiveness, nine in ten (91%) agree that satellite connectivity is the key to harnessing the full potential of IoT solutions focused on improving sustainability.

Currently, just over a third of respondents (36%) rely on satellite networks for IoT connectivity. However, satellite is set to become the most popular method of connectivity over the next decade, with half expecting to use it within this timeframe.

IoT-enabled data is not the only way satellite technology can help improve environmental outcomes. Inmarsat’s recent ‘Can Space Help Save the Planet?’ report revealed that the world could reach Net Zero by 2040 – ten years ahead of schedule – by accelerating the adoption of space and satellite technologies.

Networks such as Inmarsat ELERA are central to this, providing ultra-reliable global connectivity which allows data sharing in industries like agriculture, electrical utilities, mining, oil and gas, and transport.

Jat Brainch, Chief Commercial and Product Officer, Inmarsat said: “You cannot manage what you cannot measure, so it is heartening to see so many organisations looking to IoT to assess and improve ESG reporting.

“To demonstrate progress, however, businesses must overcome their reluctance to share useful data and have the confidence to publish meaningful insights. Otherwise, they risk undermining genuine collaboration on sustainability and overshadowing the real progress being made. There is no quick fix, but creating methodical benchmarks based on actionable data, and sharing the results, will play a critical role in re-establishing trustworthy ESG reporting.

“IoT is nothing without connectivity. Yet terrestrial coverage often cannot reach the remote locations where our most valuable data points frequently originate. By using satellites to close that connectivity gap, organisations can access data to make the right decisions right away. We need to make the most of that opportunity if we are to achieve Net Zero quickly.”

David Hill, Executive Director, IoT Community, said: “Connected IoT solutions are the key to sourcing, analysing and sharing aggregate ESG data in a compliant and secure way. The same way we use wearable devices to measure our personal health, businesses should rely on IoT solutions more to monitor progress, reduce costs, improve safety and maximise sustainability. Robust data will back up their ESG claims and can be used for reporting across all areas of their operations, particularly in remote locations with challenging conditions.

“To achieve true success, we must shift our mindset with regards to data sharing and connectivity. Once businesses become comfortable sharing their ESG insights to improve broader industry reporting and benchmarking and prioritise satellite connectivity as a key enabler, will we start to see real progress on sustainability.”

ENDS

Notes to Editors

The report ‘Accelerating sustainable action through IoT’ focuses on challenges, opportunities and priorities businesses juggle as they work to improve their sustainability credentials and the role satellite-enabled IoT solutions will play in driving this change.

This report is based on independent research conducted by Censuswide on behalf of Inmarsat, surveying 1,000+ senior technology and ESG professionals with sustainability decision-making power across a range of businesses sizes (sole trader, 1-9, 10-49, 50-99, 100-249, 250-500 and 500+ employees). Survey respondents spanned agriculture, mining, oil & gas, utilities and transport sectors across Europe, North America, South America, Africa and Asia. As such, the results represent a broad range of businesses at various stages of their sustainability and industrial IoT adoption journeys. Data was collected in August/September 2022.

ABOUT INMARSAT

Inmarsat delivers world leading, innovative, advanced and exceptionally reliable global, mobile communications across the world – in the air, at sea and on land - that are enabling a new generation of commercial, government and mission-critical services.

In November 2021, Inmarsat and Viasat announced the planned combination of the two companies, to create a new leader in global communications.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dana Dzubas
Email: press@inmarsat.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye